OA12337A - Crystalline therapeutic agent. - Google Patents

Crystalline therapeutic agent. Download PDF

Info

Publication number
OA12337A
OA12337A OA1200300008A OA1200300008A OA12337A OA 12337 A OA12337 A OA 12337A OA 1200300008 A OA1200300008 A OA 1200300008A OA 1200300008 A OA1200300008 A OA 1200300008A OA 12337 A OA12337 A OA 12337A
Authority
OA
OAPI
Prior art keywords
ethyl
compound
ethoxy
methoxyethyl
mixture
Prior art date
Application number
OA1200300008A
Other languages
English (en)
French (fr)
Inventor
Laurence James Harris
Richard Anthony Storey
Albert Shaw Wood
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0018656A external-priority patent/GB0018656D0/en
Priority claimed from GB0106464A external-priority patent/GB0106464D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of OA12337A publication Critical patent/OA12337A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
OA1200300008A 2000-07-28 2001-07-18 Crystalline therapeutic agent. OA12337A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0018656A GB0018656D0 (en) 2000-07-28 2000-07-28 Pharmaceutically active compounds
GB0106464A GB0106464D0 (en) 2001-03-15 2001-03-15 Crystalline therapeutic agent

Publications (1)

Publication Number Publication Date
OA12337A true OA12337A (en) 2006-05-15

Family

ID=26244756

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200300008A OA12337A (en) 2000-07-28 2001-07-18 Crystalline therapeutic agent.

Country Status (46)

Country Link
EP (1) EP1305314B1 (xx)
JP (1) JP2004505087A (xx)
KR (1) KR100457937B1 (xx)
CN (1) CN1207297C (xx)
AP (1) AP1400A (xx)
AR (1) AR032628A1 (xx)
AT (1) ATE286901T1 (xx)
AU (2) AU2001272690B2 (xx)
BG (1) BG107266A (xx)
BR (1) BR0112734A (xx)
CA (1) CA2417264C (xx)
CZ (1) CZ2003126A3 (xx)
DE (1) DE60108398T2 (xx)
DO (1) DOP2001000217A (xx)
DZ (1) DZ3364A1 (xx)
EA (1) EA004681B1 (xx)
EC (1) ECSP034454A (xx)
EE (1) EE200300045A (xx)
ES (1) ES2231521T3 (xx)
GE (1) GEP20053494B (xx)
HK (1) HK1055954A1 (xx)
HR (1) HRP20030061A2 (xx)
HU (1) HUP0302982A3 (xx)
IL (1) IL153226A0 (xx)
IN (1) IN2002MU01649A (xx)
IS (1) IS6626A (xx)
MA (1) MA26931A1 (xx)
MX (1) MX233602B (xx)
MY (1) MY117831A (xx)
NO (1) NO324220B1 (xx)
NZ (1) NZ523226A (xx)
OA (1) OA12337A (xx)
PA (1) PA8523501A1 (xx)
PE (1) PE20020277A1 (xx)
PH (1) PH12001001922B1 (xx)
PL (1) PL365133A1 (xx)
PT (1) PT1305314E (xx)
SK (1) SK572003A3 (xx)
SV (1) SV2001000570A (xx)
TN (1) TNSN01112A1 (xx)
TW (1) TWI285643B (xx)
UA (1) UA72631C2 (xx)
UY (1) UY26854A1 (xx)
WO (1) WO2002010171A1 (xx)
YU (1) YU4703A (xx)
ZA (1) ZA200301457B (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072079A1 (en) * 2003-02-11 2004-08-26 Pfizer Limited Hydrated and anhydrous sildenafil hemi-citrate compound
JP4015176B2 (ja) 2003-04-29 2007-11-28 ファイザー・インク 高血圧症の治療に有用な５，７−ジアミノピラゾロ４，３−ジピリミジン類
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
BRPI0509731A (pt) 2004-04-07 2007-09-25 Pfizer pirazol[4,3-d]pirimidinas
PT1881985E (pt) 2005-05-12 2011-02-01 Pfizer Formas cristalinas anidras de n-[1-(2-etoxietil)-5-(n- -etil-n-metilamino)-7-(4-metilpiridin-2-il-amino)-1h- -pirazolo[4,3-d]pirimidino-3-carbonil]metanossulfonamida

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1073658B1 (en) * 1998-04-20 2003-08-13 Pfizer Inc. Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them

Also Published As

Publication number Publication date
ES2231521T3 (es) 2005-05-16
GEP20053494B (en) 2005-04-25
EP1305314B1 (en) 2005-01-12
AU2001272690B2 (en) 2005-12-08
SV2001000570A (es) 2002-09-03
ATE286901T1 (de) 2005-01-15
TWI285643B (en) 2007-08-21
AR032628A1 (es) 2003-11-19
AU7269001A (en) 2002-02-13
EA200300079A1 (ru) 2003-06-26
UY26854A1 (es) 2002-02-28
YU4703A (sh) 2006-01-16
HUP0302982A3 (en) 2005-01-28
TNSN01112A1 (fr) 2005-11-10
NO324220B1 (no) 2007-09-10
MA26931A1 (fr) 2004-12-20
IN2002MU01649A (xx) 2004-12-11
HUP0302982A2 (hu) 2003-12-29
DZ3364A1 (fr) 2002-02-07
EE200300045A (et) 2004-12-15
IS6626A (is) 2002-11-18
BG107266A (bg) 2003-07-31
WO2002010171A1 (en) 2002-02-07
AP1400A (en) 2005-04-28
PH12001001922B1 (en) 2006-11-21
MXPA03000856A (es) 2003-06-06
CZ2003126A3 (cs) 2004-02-18
KR20030016430A (ko) 2003-02-26
SK572003A3 (en) 2004-05-04
ZA200301457B (en) 2004-04-28
NO20030416L (no) 2003-02-05
CN1444585A (zh) 2003-09-24
PL365133A1 (en) 2004-12-27
EA004681B1 (ru) 2004-06-24
KR100457937B1 (ko) 2004-11-20
CA2417264C (en) 2007-06-12
UA72631C2 (uk) 2005-03-15
CA2417264A1 (en) 2002-02-07
MY117831A (en) 2004-08-30
PA8523501A1 (es) 2002-10-24
BR0112734A (pt) 2004-08-10
NO20030416D0 (no) 2003-01-27
EP1305314A1 (en) 2003-05-02
MX233602B (es) 2006-01-10
HK1055954A1 (en) 2004-01-30
PE20020277A1 (es) 2002-05-11
DE60108398D1 (de) 2005-02-17
JP2004505087A (ja) 2004-02-19
DOP2001000217A (es) 2002-10-30
PT1305314E (pt) 2005-04-29
CN1207297C (zh) 2005-06-22
IL153226A0 (en) 2003-07-06
HRP20030061A2 (en) 2003-04-30
DE60108398T2 (de) 2005-12-22
ECSP034454A (es) 2003-03-10
AP2001002234A0 (en) 2001-09-30
NZ523226A (en) 2003-07-25

Similar Documents

Publication Publication Date Title
EP1220856B1 (en) Pyrazolo[4,3-d]pyrimidine derivatives
EP1372656B1 (en) Pyrazolo[4,3-d]pyrimidinone compounds as cgmp pde inhibitors
NZ566087A (en) Novel crystalline form of 7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4, 5-b]indole-1-acetamide
US20010049439A1 (en) Therapeutic polymorphs of a GABA-A alpha-5 inverse agonist and pamoate formulations of the same
OA12337A (en) Crystalline therapeutic agent.
US6420557B1 (en) Crystalline therapeutic agent
AU2001272690A1 (en) Crystalline therapeutic agent
US6350751B1 (en) Therapeutic agents
EP1220855B1 (en) Anhydrous salt
JP2003128653A (ja) 結晶性物質